A detailed history of Parallel Advisors, LLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 280 shares of TSHA stock, worth $562. This represents 0.0% of its overall portfolio holdings.

Number of Shares
280
Previous 280 -0.0%
Holding current value
$562
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$2.04 - $4.17 $571 - $1,167
280 New
280 $0
Q1 2022

Apr 28, 2022

SELL
$5.22 - $11.86 $234 - $533
-45 Closed
0 $0
Q4 2021

Jan 20, 2022

BUY
$11.43 - $19.2 $514 - $864
45 New
45 $1,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $97.2M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.